Modulation of T cell metabolism thus may represent a new therapeutic avenue for leukemia patients.

High levels of blood markers for vascular endothelial dysfunction were associated with longer periods of confusion in ICU patients, Vanderbilt researchers have discovered.

Vanderbilt researchers developed a new algorithm to find clinically targetable gene rearrangements in cancers.

A multi-center research team including scientists from the Vanderbilt Vaccine Center has come up with a clever “Trojan Horse” strategy for thwarting the highly lethal Ebola virus.

A protein called Gremlin 2 controls the extent of inflammation after heart attack and may be a good therapeutic target.

William Tansey, Ph.D., professor of Cell Development and Biology and Ingram Professor of Cancer Research, has been awarded a two-year, $250,000 grant from Alex’s Lemonade Stand Foundation (ALSF) to study malignant rhabdoid tumors (MRTs).

A consortium led by Vanderbilt University Medical Center (VUMC) researchers has received funding as it makes plans for a multicenter trial that could determine whether deep brain stimulation (DBS) slows the progression of Parkinson’s disease in early-stage patients.